Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 97-102

  Chen, Hengyi ^a   Yao, Wenxiu ^b   Chu, Qian ^c   Han, Rui ^a   Wang, Yubo ^a   Sun, Jianguo ^d   Wang, Dong ^a   Wang, Yongsheng ^e   Cao, Mengshu ^f   He, Yong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

^f MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Diabetes; EGFR activating mutations; EGFR TKI; Metformin; NSCLC

Indexed keywords

ACARBOSE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLITAZONE DERIVATIVE; ICOTINIB; INSULIN; METFORMIN; SULFONYLUREA; ANTINEOPLASTIC AGENT; CROWN ETHER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHINA; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DIABETES MELLITUS, TYPE 2; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84943457091     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.024     Document Type: Article

References (39)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med 2009, 361:947-957.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
4. Ettinger D.S., Wood D.E., Akerley W., Bazhenova L.A., Borghaei H., Camidge D.R., et al. Non-small cell lung cancer, version 1. J. Natl Compr. Canc. Netw 2015, 12(2014):1738-1761.
5. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
6. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
7. Lee C.C., Shiao H.Y., Wang W.C., Hsieh H.P. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin. Investig. Drugs 2014, 23:1333-1348.
8. Sequist L.V., Soria J.C., Goldman J.W., Wakelee H.A., Gadgeel S.M., Varga A., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med 2015, 372:1700-1709.
9. Wheler J.J., Tsimberidou A.M., Falchook G.S., Zinner R.G., Hong D.S., Fok J.Y., et al. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol. Cancer Ther 2013, 12:2167-2175.
10. Janjigian Y.Y., Azzoli C.G., Krug L.M., Pereira L.K., Rizvi N.A., Pietanza M.C., et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res 2011, 17:2521-2527.
11. Tsai M.J., Yang C.J., Kung Y.T., Sheu C.C., Shen Y.T., Chang P.Y., et al. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner. Lung Cancer 2014, 86:137-143.
12. Smiechowski B.B., Azoulay L., Yin H., Pollak M.N., Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013, 36:124-129.
13. Tan B.X., Yao W.X., Ge J., Peng X.C., Du X.B., Zhang R., et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011, 117:5103-5111.
14. Lin J.J., Gallagher E.J., Sigel K., Mhango G., Galsky M.D., Smith C.B., et al. Survival of stage IV lung cancer patients with diabetes treated with metformin. Am. J. Respir. Crit. Care Med 2015, 191:448-454.
15. Li L., Han R., Xiao H., Lin C., Wang Y., Liu H., et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res 2014, 20:2714-2726.
16. Zhao Z., Cheng X., Wang Y., Han R., Li L., Xiang T., et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS ONE 2014, 9:e95884.
17. Dias-Santagata D., Akhavanfard S., David S.S., Vernovsky K., Kuhlmann G., Boisvert S.L., et al. Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med 2010, 2:146-158.
18. Sequist L.V., Joshi V.A., Jänne P.A., Bell D.W., Fidias P., Lindeman N.I., et al. Epidermal growth factor receptor mutatin testing in the care of lung cancer patients. Clin. Cancer Res 2006, 12:4403s-4408s.
19. International Classification of Diseases for Oncology: ICD-O 2000, World Health Organization, Geneva. third ed. A.G. Fritz (Ed.).
20. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45:228-247.
21. Cho S.W., Yi K.H., Han S.K., Sun H.J., Kim Y.A., Oh B.C., et al. Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Mol. Cell. Endocrinol 2014, 393:24-29.
22. Lengyel E., Litchfield L.M., Mitra A.K., Nieman K.M., Mukherjee A., Zhang Y., et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol 2015, 212:479.e1-479.e10.
23. Lau Y.K., Du X., Rayannavar V., Hopkins B., Shaw J., Bessler E., et al. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget 2014, 5:10503-10517.
24. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
25. Kim S.M., Kwon O.J., Hong Y.K., Kim J.H., Solca F., Ha S.J., et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther 2012, 11:2254-2264.
26. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
27. Peled N., Wynes M.W., Ikeda N., Ohira T., Yoshida K., Qian J., et al. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol. (Dordr.) 2013, 36:277-288.
28. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
29. Uramoto H., Iwata T., Onitsuka T., Shimokawa H., Hanagiri T., Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010, 30:2513-2517.
30. Appleman L.J. MET signaling pathway: a rational target for cancer therapy. J. Clin. Oncol 2011, 29:4837-4838.
31. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66:10100-10111.
32. Xie M., Zhang L., He C.S., Xu F., Liu J.L., Hu Z.H., et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J. Cell. Biochem 2012, 113:1501-1513.
33. Rocha G.Z., Dias M.M., Ropelle E.R., Osório-Costa F., Rossato F.A., Vercesi A.E., et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res 2011, 17:3993-4005.
34. Ben Sahra I., Tanti J.F., Bost F. The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010, 6:670-671.
35. Salani B., Maffioli S., Hamoudane M., Parodi A., Ravera S., Passalacqua M., et al. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J. 2012, 26:788-798.
36. Morgillo F., Sasso F.C., Della Corte C.M., Vitagliano D., D'Aiuto E., Troiani T., et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin. Cancer Res 2013, 19:3508-3519.
37. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014, 15:1236-1244.
38. Johson J.A., Gale E.A. Diabetes, insulin use, and cancer risk: are observational studies part of the solution or part of the problem?. Diabetes 2010, 59:1129-1131.
39. Wu Y., Liu H.B., Shi X.F., Song Y. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS ONE 2014, 9. e99577.